J-WDMC Precision Therapeutics 

Tumor-Specific Universal Cancer Drugs 

Tumor-Specific Universal Cancer Drugs that do Not Bind to Normal Tissues

        Our invention “Tumor-Specific-Targeting-Platform” specifically target tumor, does not bind to normal tissues: It is low toxicity to patients. Its low DLT (dose-limiting toxicity) can maximize drug dose and therapy efficacy.  It can reduce cancer therapy-induced patient death, side-effects, complex diseases, lifespan shortening & secondary cancers.

          In comparison, current anticancer drugs/CAR-T targeting to CEACAM5, CEACAM6, Nectin-4, BCMA, CD19, CD20, CD30, CD38, CD40, CD44v6, CD47, CD70, CD73, CTLA-4, FRα, EGFR, Caprin-1, GPC3, Integrin, PD-L1, Trop2, CLDN18.2, PSMA, HER2, HER3, DLL3, TIGIT, PTK7, VEGF, c-Met, B7-H3, & B7-H4…etc., developing by AbbVie, AstraZeneca, BMS, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck, Pfizer, Roche, & Takeda…etc., show strong binding to normal tissues. These drugs can lead to severe organ damages and life-threatening toxicities. Also, their high DLTs limit drug dose in patients, thus they have low therapy efficacies.

        Many failed/discontinued clinical trials of current ADC drugs targeting to CD47, TIGIT, DLL3, HER2, HER3, Integrin, PTK7, FRα, CD44v6, PD-L1, EGFR, Nectin4, CD70, Trop2, PSMA, CEACAM5, CD73, VEGF, c-Met, and B7-H3…etc., were reported due to severe toxicity and limited efficacy in patients.

    We filed patents in 2026 to get 20+7 years patent protection in most countries worldwide. Utility of our platform:

1.  Antibody-contrast agent for image-guided precision cancer surgery.

2.  Antibody-imaging agent for precision radiotherapy.

3.  Antibody-contrast agent for contrast-enhanced CT, MRI, and PET tumor imaging. 

4.  Antibody-drug conjugates (ADCs), antibody radio-drug conjugate (ARC), peptide-drug conjugates.

5.  Degrader-Antibody Conjugates (DACs) for targeted protein degraders to kill tumors.

6.  CAR-T therapy and CAR-NK therapy.

7.  Bispecific T-cell Engagers (BiTEs): bispecific antibody for cancer immunotherapy.

8.  Antibody-cell conjugates (ACCs).

9.  T-cell receptor-mimic (TCRm) antibodies.

10. Cancer vaccines: DNA, RNA, protein, & peptide cancer vaccines.

11. Nanoparticles for targeted magnetic hyperthermia therapy.

Contact: info@j-wdmc.com